Olbricht C J, Schulzeck P
Division of Nephrology, Hannover Medical School, Federal Republic of Germany.
ASAIO Trans. 1991 Jul-Sep;37(3):M492-3.
Five patients with diet and drug resistant familial hypercholesterolemia (FH) (low density lipoprotein [LDL] cholesterol, LDL greater than 230 mg/dl) were treated by LDL apheresis, using dextran sulfate cellulose adsorption (DSC), to prevent coronary heart disease (CHD). After membrane plasma separation, two 150 ml columns of DSC alternately adsorbed LDL, and were regenerated by 4.1% saline. Five patients received 230 treatments with 7 to 14 days intervals over 6 to 30 months. The treated plasma volume per session was 3.8 +/- 0.6 L. Post-apheresis values in percent of pre-apheresis were: total cholesterol, 42%; LDL, 27%; VLDL, 62%; HDL, 96%; triglycerides, 70%; WBC, 115%; platelets, 88%; C3 complement, 78%; fibrinogen, 67%; albumin, 94% (p less than or equal to 0.005 for all values). Safety parameters showed only slight changes. The initial LDL of 436 +/- 172 mg/dl decreased to nonatherogenic levels of between 150 and 100 mg/dl, whereas high density lipoprotein remained unchanged. Adverse events (hypotension, angina pectoris, technical problems) occurred in six treatments. Long-term treatment of patients with therapy resistant FH by extracorporeal DSC adsorption is effective and safe.
五名患有饮食和药物抵抗性家族性高胆固醇血症(FH)(低密度脂蛋白[LDL]胆固醇,LDL大于230mg/dl)的患者接受了低密度脂蛋白去除术治疗,采用硫酸葡聚糖纤维素吸附(DSC)法,以预防冠心病(CHD)。在进行膜血浆分离后,两根150ml的DSC柱交替吸附LDL,并用4.1%的盐水进行再生。五名患者在6至30个月内接受了230次治疗,间隔时间为7至14天。每次治疗的处理血浆量为3.8±0.6L。去除术后的值相对于术前的百分比为:总胆固醇,42%;LDL,27%;极低密度脂蛋白(VLDL),62%;高密度脂蛋白(HDL),96%;甘油三酯,70%;白细胞(WBC),115%;血小板,88%;补体C3,78%;纤维蛋白原,67%;白蛋白,94%(所有值p≤0.005)。安全参数仅显示出轻微变化。初始LDL为436±172mg/dl降至150至100mg/dl的非致动脉粥样硬化水平,而高密度脂蛋白保持不变。六次治疗中发生了不良事件(低血压、心绞痛、技术问题)。通过体外DSC吸附对治疗抵抗性FH患者进行长期治疗是有效且安全的。